.infobox .infobox-protein
{
float: right;
width: 300px;
padding: 10px;
background: #f8f9fa;
border: 1px solid #ddd;
border-radius: 4px;
margin: 10px;
}
.infobox .infobox-protein th
{
background: #28a745;
color: white;
padding: 8px;
}
.infobox .infobox-protein td
{
padding: 6px;
}
VPS35 (Vacuolar Protein Sorting 35) is a critical component of the retromer complex, which plays essential roles in intracellular protein trafficking. This page provides comprehensive information about the structure, function, and disease relevance of VPS35 protein in neurodegenerative processes.
VPS35 is the core scaffolding protein of the retromer complex, which consists of VPS26, VPS29, and VPS35. The retromer is responsible for retrograde transport of cargo proteins from endosomes to the trans-Golgi network, as well as cargo recycling to the plasma membrane. This trafficking function is critical for maintaining neuronal protein homeostasis and synaptic function.
VPS35 consists of a beta-propeller repeat structure that forms the core of the retromer complex. The protein has an elongated structure with distinct binding sites for VPS26 and VPS29. A PDZ-binding motif at the C-terminus interacts with various cargo proteins.
VPS35 is a core component of the retromer complex (VPS26-VPS29-VPS35), which mediates retrograde transport of cargo from endosomes to the trans-Golgi network. The retromer plays a critical role in sorting proteins involved in synaptic function, receptor signaling, and protein homeostasis. It is essential for recycling transmembrane proteins including the Wntless receptor, cation-independent mannose-6-phosphate receptor, and glutamate receptors.
Mutations in VPS35 cause autosomal dominant late-onset Parkinson's disease (PARK17). The D620N mutation is the most common pathogenic variant, causing impaired retromer function. Defective retromer trafficking contributes to alpha-synuclein aggregation and mitochondrial dysfunction in PD. Reduced retromer function is also observed in AD and ALS.
Retromer-enhancing small molecules are being developed to treat neurodegenerative diseases. These include the pharmacological chaperone R55 and novel compounds that stabilize the retromer complex. Gene therapy approaches to increase VPS35 expression are also being explored.
The study of Vps35 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.